Danaher Corporation $DHR Stock Sold by Douglas Lane & Associates LLC

Douglas Lane & Associates LLC trimmed its stake in shares of Danaher Corporation (NYSE:DHR) by 0.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 456,372 shares of the conglomerate’s stock after selling 3,044 shares during the period. Danaher accounts for 1.2% of Douglas Lane & Associates LLC’s portfolio, making the stock its 20th largest holding. Douglas Lane & Associates LLC owned approximately 0.06% of Danaher worth $101,109,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in DHR. Main Street Group LTD bought a new stake in shares of Danaher in the 1st quarter worth about $25,000. N.E.W. Advisory Services LLC purchased a new position in shares of Danaher in the 2nd quarter worth approximately $25,000. Hilton Head Capital Partners LLC purchased a new stake in Danaher during the 4th quarter valued at $27,000. Clal Insurance Enterprises Holdings Ltd boosted its stake in Danaher by 71.6% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 127 shares of the conglomerate’s stock worth $29,000 after buying an additional 53 shares during the period. Finally, Evolution Wealth Management Inc. increased its position in Danaher by 208.0% during the first quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock valued at $29,000 after acquiring an additional 104 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 1.0%

NYSE DHR traded up $2.10 during trading on Friday, hitting $219.56. The company’s stock had a trading volume of 1,113,624 shares, compared to its average volume of 4,446,542. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The company has a market cap of $154.35 billion, a PE ratio of 38.99, a P/E/G ratio of 2.72 and a beta of 0.76. The business’s 50 day simple moving average is $210.88 and its 200-day simple moving average is $194.44. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The business had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same period in the prior year, the company earned $0.77 earnings per share. The company’s revenue was up 5.5% on a year-over-year basis. On average, equities analysts anticipate that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s payout ratio is 28.42%.

Wall Street Analyst Weigh In

DHR has been the topic of several recent analyst reports. Evercore reiterated an “outperform” rating and issued a $230.00 price target on shares of Danaher in a report on Monday, July 6th. Piper Sandler began coverage on Danaher in a report on Thursday, June 11th. They issued a “neutral” rating and a $200.00 price target for the company. Stifel Nicolaus decreased their target price on Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. UBS Group began coverage on Danaher in a report on Wednesday, September 9th. They issued a “buy” rating and a $250.00 price objective for the company. Finally, Barclays boosted their price target on shares of Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $235.23.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.